San Diego, CA (PRWEB) June 01, 2011
Silicon Kinetics Inc., the innovative proteomics tool company which introduced the world’s first 3D biosensor surface for label-free biomolecular interaction analysis, announced that Dr. John Ervin has been appointed President. Dr. Ervin previously served as Director of R&D and Engineering for the Company.
“John will lead the commercial as well as the technical activities of Silicon Kinetics,” said Hus Tigli, Chairman and CEO. “Silicon Kinetics is fortunate to have John’s talent and experience, as we expand the applications for our SKi Pro platform, deploying nano-pore optical interferometry (NPOI) for standard biomolecular interactions as well as affinity capture on our 3D surfaces.”
Dr. Ervin has devoted his entire career to the life sciences tools industry focusing on the development of novel tools for separation, purification and analysis of biomaterials. Prior to Silicon Kinetics, Dr. Ervin was at Eksigent, Ultradots, and PerSeptive Biosystems. He holds a BS from Cornell University and a PhD in Physical Chemistry from the University of Illinois.
Silicon Kinetics also announced the addition of Dr. Ervin and Robert Fein to its Board of Directors. Mr. Fein is a Managing Director of Back Bay Management Consulting Group, a sponsor of venture capital investments, based in Boston, Massachusetts. He also served as VP Business Development for Trex Enterprises Corporation, responsible for spin-off activities, including the founding of Silicon Kinetics. He was previously an officer and founder of NewRiver, Inc. (sold to Broadridge) and PerSeptive Biosystems (sold to Life Technologies). He was also the Director of Corporate Strategy of Thermo Electron Corporation (Thermo Fisher Scientific). Mr. Fein is a graduate of Yale University and Harvard Law School.
Silicon Kinetics recently announced the validation of its unique AC-MS (Affinity Capture- Mass Spectroscopy) application by prominent pharma/biotech companies. AC-MS is a technique that combines the sensitivity of NPOI with the information richness of MS. In a single technique, both the binding parameters can be measured and the identity of an unknown analyte can be determined with the most sensitive level of detection. As such, the AC-MS tool is the optimal one for drug screening and other applications.
About Silicon Kinetics
Silicon Kinetics, Inc. is a privately-held life sciences tools company headquartered in San Diego, California. The Company specializes in instruments for optical interferometry in nano-porous silicon biochips. The SKi Pro™ instrument platform and the 3D SKi Sensor™ biochips are used to detect protein-protein, protein-drug, or protein-DNA interactions in real-time and quantify binding kinetics, dissociation rates, or biomolecular affinity rankings, required for the study of disease pathways and the development and manufacturing of therapeutics. More information can be found at http://www.siliconkinetics.com.
Martin Latterich, PhD
Silicon Kinetics Inc.